Back to Newsroom
Back to Newsroom

Abivax Announces Annual Ordinary and Extraordinary General Meeting on June 9, 2022, and the Availability of the Preparatory Documents

Wednesday, May 18, 2022 12:20 PM

PARIS, FRANCE / ACCESSWIRE / May 18, 2022 / Abivax SA (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, informs its shareholders that its ordinary and extraordinary general meeting will be held on June 9, 2022, at 10:00 a.m. (CEST), at the offices of Dechert (Paris) LLP, located at 32 rue de Monceau in Paris (75008), France.

The Shareholders' Meeting documents and information and the voting form have been made available to Shareholders under the terms and conditions specified by current French regulations, and are available on the Company's website . All documents are exclusively available in French.


About Abivax (

Abivax, a clinical stage biotechnology company, is developing novel therapies that modulate the body's natural immune machinery to treat patients with chronic inflammatory diseases, viral infections, and cancer. Abivax is listed on Euronext compartment B (ISIN: FR0012333284 - Mnémo: ABVX). Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, ABX464 to treat severe inflammatory diseases, and ABX196 to treat hepatocellular carcinoma. More information on the company is available at . Follow us on Twitter @ABIVAX_.


Regina Jehle
[email protected]
+33 6 24 50 69 63

LifeSci Advisors
Ligia Vela-Reid
[email protected]
+44 7413 825310

Press Relations & Investors Europe
MC Services AG
Anne Hennecke
[email protected]
+49 211 529 252 22

Public Relations France
Ghislaine Gasparetto
[email protected]
+33 6 21 10 49 24

Public Relations France
Thomas Roborel de Climens
[email protected]
+33 6 78 12 97 95

Public Relations USA
Rooney Partners LLC
Jeanene Timberlake
[email protected]
+1 646 770 8858


Shareholder Meeting
Back to newsroom
Back to Newsroom